218 related articles for article (PubMed ID: 20880503)
1. Rebuilding synaptic architecture in HIV-1 associated neurocognitive disease: a therapeutic strategy based on modulation of mixed lineage kinase.
Gelbard HA; Dewhurst S; Maggirwar SB; Kiebala M; Polesskaya O; Gendelman HE
Neurotherapeutics; 2010 Oct; 7(4):392-8. PubMed ID: 20880503
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation.
Sui Z; Fan S; Sniderhan L; Reisinger E; Litzburg A; Schifitto G; Gelbard HA; Dewhurst S; Maggirwar SB
J Immunol; 2006 Jul; 177(1):702-11. PubMed ID: 16785569
[TBL] [Abstract][Full Text] [Related]
3. Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Goodfellow VS; Loweth CJ; Ravula SB; Wiemann T; Nguyen T; Xu Y; Todd DE; Sheppard D; Pollack S; Polesskaya O; Marker DF; Dewhurst S; Gelbard HA
J Med Chem; 2013 Oct; 56(20):8032-48. PubMed ID: 24044867
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a role of mixed lineage kinases in neuronal apoptosis.
Mota M; Reeder M; Chernoff J; Bazenet CE
J Neurosci; 2001 Jul; 21(14):4949-57. PubMed ID: 11438570
[TBL] [Abstract][Full Text] [Related]
5. The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders.
Marker DF; Tremblay MÈ; Puccini JM; Barbieri J; Gantz Marker MA; Loweth CJ; Muly EC; Lu SM; Goodfellow VS; Dewhurst S; Gelbard HA
J Neurosci; 2013 Jun; 33(24):9998-10010. PubMed ID: 23761895
[TBL] [Abstract][Full Text] [Related]
6. Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling.
Zhang H; Wu W; Du Y; Santos SJ; Conrad SE; Watson JT; Grammatikakis N; Gallo KA
J Biol Chem; 2004 May; 279(19):19457-63. PubMed ID: 15001580
[TBL] [Abstract][Full Text] [Related]
7. Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages.
Saminathan P; Kevadiya BD; Marker DF; Gendelman HE; Gorantla S; Gelbard HA
J Neuroimmune Pharmacol; 2019 Mar; 14(1):44-51. PubMed ID: 30617749
[TBL] [Abstract][Full Text] [Related]
8. The JNK/SAPK activator mixed lineage kinase 3 (MLK3) transforms NIH 3T3 cells in a MEK-dependent fashion.
Hartkamp J; Troppmair J; Rapp UR
Cancer Res; 1999 May; 59(9):2195-202. PubMed ID: 10232608
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades.
Wang MJ; Huang HY; Chen WF; Chang HF; Kuo JS
J Neuroinflammation; 2010 Dec; 7():99. PubMed ID: 21194439
[TBL] [Abstract][Full Text] [Related]
10. K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways.
Pan J; Wang G; Yang HQ; Hong Z; Xiao Q; Ren RJ; Zhou HY; Bai L; Chen SD
Mol Pharmacol; 2007 Dec; 72(6):1607-18. PubMed ID: 17855652
[TBL] [Abstract][Full Text] [Related]
11. Mixed lineage kinase 3 connects reactive oxygen species to c-Jun NH2-terminal kinase-induced mitochondrial apoptosis in genipin-treated PC3 human prostate cancer cells.
Hong HY; Kim BC
Biochem Biophys Res Commun; 2007 Oct; 362(2):307-12. PubMed ID: 17707342
[TBL] [Abstract][Full Text] [Related]
12. Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells.
Kim KY; Kim BC; Xu Z; Kim SJ
J Biol Chem; 2004 Jul; 279(28):29478-84. PubMed ID: 15069087
[TBL] [Abstract][Full Text] [Related]
13. S-nitrosylation of mixed lineage kinase 3 contributes to its activation after cerebral ischemia.
Hu SQ; Ye JS; Zong YY; Sun CC; Liu DH; Wu YP; Song T; Zhang GY
J Biol Chem; 2012 Jan; 287(4):2364-77. PubMed ID: 22123824
[TBL] [Abstract][Full Text] [Related]
14. Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3.
Mishra R; Barthwal MK; Sondarva G; Rana B; Wong L; Chatterjee M; Woodgett JR; Rana A
J Biol Chem; 2007 Oct; 282(42):30393-405. PubMed ID: 17711861
[TBL] [Abstract][Full Text] [Related]
15. Heme Oxygenase-1 Inhibits Neuronal Apoptosis in Spinal Cord Injury through Down-Regulation of Cdc42-MLK3-MKK7-JNK3 Axis.
Lin W; Wang S; Yang Z; Lin J; Ke Q; Lan W; Shi J; Wu S; Cai B
J Neurotrauma; 2017 Feb; 34(3):695-706. PubMed ID: 27526795
[TBL] [Abstract][Full Text] [Related]
16. The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss.
Kline EM; Butkovich LM; Bradner JM; Chang J; Gelbard H; Goodfellow V; Caudle WM; Tansey MG
Exp Neurol; 2019 Aug; 318():157-164. PubMed ID: 31077715
[TBL] [Abstract][Full Text] [Related]
17. Dynamic positive feedback phosphorylation of mixed lineage kinase 3 by JNK reversibly regulates its distribution to Triton-soluble domains.
Schachter KA; Du Y; Lin A; Gallo KA
J Biol Chem; 2006 Jul; 281(28):19134-44. PubMed ID: 16687404
[TBL] [Abstract][Full Text] [Related]
18. Cytokine-induced activation of mixed lineage kinase 3 requires TRAF2 and TRAF6.
Korchnak AC; Zhan Y; Aguilar MT; Chadee DN
Cell Signal; 2009 Nov; 21(11):1620-5. PubMed ID: 19586614
[TBL] [Abstract][Full Text] [Related]
19. The neuroprotective effects of K252a through inhibiting MLK3/MKK7/JNK3 signaling pathway on ischemic brain injury in rat hippocampal CA1 region.
Pan J; Zhang QG; Zhang GY
Neuroscience; 2005; 131(1):147-59. PubMed ID: 15680699
[TBL] [Abstract][Full Text] [Related]
20. Mixed-lineage kinase 3 deficiency promotes neointima formation through increased activation of the RhoA pathway in vascular smooth muscle cells.
Gadang V; Konaniah E; Hui DY; Jaeschke A
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1429-36. PubMed ID: 24790140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
